An expert opinion on the current treatment of anemia in patients with kidney disease

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 4, 2012, Pages 495-503

  Locatelli, Francesco ^a   Vecchio, Lucia Del ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

Anemia; Chronic kidney disease; Erythropoiesis stimulating agents; Hemoglobin; Mortality; Target

Indexed keywords

ANDROGEN; BIOSIMILAR AGENT; C REACTIVE PROTEIN; CARBOHYDRATE; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; DRUG RECEPTOR; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANDROGEN THERAPY; ANEMIA; BIOEQUIVALENCE; BLOOD TRANSFUSION; CANCER PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES MELLITUS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG MARKETING; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; HEMODIALYSIS; HUMAN; INFLAMMATION; INFORMATION RETRIEVAL; IRON DEFICIENCY ANEMIA; MORTALITY; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; REVASCULARIZATION; REVIEW; STROKE; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT RESPONSE;

ANEMIA; BIOSIMILAR PHARMACEUTICALS; CLINICAL TRIALS, PHASE III AS TOPIC; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY DISEASES;

EID: 84857268648     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.658369     Document Type: Review

References (57)

1. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34(1):125-34 (Pubitemid 29318806)
2. Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988 - 1994). Arch Intern Med 2002;162(12):1401-8 (Pubitemid 34655201)
3. Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J 1993;70:357-62 (Pubitemid 23309546)
4. Ma J, Ebben J, Xia H, Collins A. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-19 (Pubitemid 29117643)
5. Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001;12(11):2465-73 (Pubitemid 33021125)
6. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44(1):94-111 (Pubitemid 38880932)
7. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004;19(1):121-32 (Pubitemid 38072623)
8. Volkova N, Arab L. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis 2006;47(1):24-36 (Pubitemid 41828263)
9. Winearls CG, Oliver DO, Pippard MJ, et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;2:1175-8
10. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-8 (Pubitemid 17052741)
11. Storring PL, Tiplady RJ, Gaines Das RE, et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998;100:79-89 (Pubitemid 28051844)
12. Powell JS, Berkner KL, Lebo RV, et al. Human erythropoietin gene: high level expression in stably transfected mammalian cells and chromosome localization. Proc Natl Acad Sci USA 1986;83:6465-9 (Pubitemid 17174755)
13. Nimtz M, Martin W, Wray V, et al. Structures of sialylated oligosaccharides of human erythropoietin expressed in recombinant BHK-21 cells. Eur J Biochem 1993;213:39-56 (Pubitemid 23106030)
14. Minghetti P, Rocco P, Cilurzo F, et al. The regulatory framework of biosimilars in the European Union. Drug Discov Today 2012;17(1-2):63-70
15. Lonnemann G, Wrenger E. Biosimilar epoetin zeta in nephrology: a single-dialysis center experience. Clin Nephrol 2011;75(1):59-62
16. Schellekens H. Assessing the bioequivalence of biosimilars The Retacrit case. Drug Discov Today 2009;14(9-10):495-9
17. Brinks V, Hawe A, Basmeleh AH, et al. Quality of original and biosimilar epoetin products. Pharm Res 2011;28(2):386-9
18. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 1998;339:578-83 (Pubitemid 28385654)
19. Egrie JC, Browne KJ. Development and characterisation of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001;16:Suppl 3):3-13 (Pubitemid 32591159)
20. Locatelli F, Olivares J, Walker R, et al. European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001;60(2):741-7 (Pubitemid 32678918)
21. Locatelli F, Canaud B, Giacardy F, et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003;18(2):362-9 (Pubitemid 36181689)
22. Vanrenterghem Y, Barany P, Mann JF, et al. European/Australian NESP 970200 Study Group. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002;62(6):2167-75 (Pubitemid 35366172)
23. Mann J, Kessler M, Villa G, et al. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials. Clin Nephrol 2007;67(3):140-8 (Pubitemid 46416374)
24. Aranesp Summary of Product Characteristics. 2006. Available from: http://www.emea.europa.eu/humandocs/ PDFs/EPAR/aranesp/H-332-PI-en.pdf
25. Aarup M, Bryndum J, Dieperink H, et al. Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrol Dial Transplant 2006;21(5):1312-16
26. Brandt M, Lazendorfer M, Frische J, et al. Different receptor binding activity of C.E.R.A. (continuous erythropoietin receptor activator) compared with epoetin beta determined by surface plasmon resonance and competition assay on UT-7 cells [abstract SO018). Nephrol Dial Transplant 2006;21(Suppl 4):iv9
27. Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005;4(6):436-40
28. Locatelli F, Villa G, De Francisco ALM, et al. Effect of a continuous erythropoietin receptor activator (C.E.R. A.) on stable haemoglobin in patients with CKD on dialysis. Curr Med Res Opin 2007;23:969-79 (Pubitemid 46799579)
29. Levin NW, Fishbane S, Canedo FV, et al. MAXIMA study investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007;370(9596):1415-21 (Pubitemid 47576167)
30. Macdougall IC, Walker R, Provenzano R, et al. ARCTOS Study Investigators. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008;3(2):337-47
31. Roger SD, Locatelli F, Woitas RP, et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant 2011;26(12):3980-6
32. Carrera F, Lok CE, de Francisco A, et al. PATRONUS Investigators. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant 2010;25(12):4009-17
33. Mann JF, de Francisco A, Nassar G, Canaud B. Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease. Clin Nephrol 2011;76(1):9-15
34. Alfrey CP, Fishbane S. Implications of neocytolysis for optimal management of anaemia in chronic kidney disease. Nephron Clin Pract 2007;106(4):c149-56 (Pubitemid 47172274)
35. Del Vecchio L, Pozzoni P, Andrulli S, Locatelli F. Inflammation and resistance to treatment with recombinant human erythropoietin. J Ren Nutr 2005;15(1):137-41 (Pubitemid 40093698)
36. Locatelli F, Andrulli S, Memoli B, et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 2006;21(4):991-8
37. Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008;52(4):727-36
38. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008;74(6):791-8
39. Locatelli F, Del Vecchio L. Erythropoietic response to erythropoiesis-stimulating agents and outcome: should we give up the haemoglobin target approach? Nephrol Dial Transplant 2011;26(7):2069-71
40. Solomon SD, Uno H, Lewis EF, et al. Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010;363(12):1146-55
41. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;335:2071-84 (Pubitemid 44749316)
42. Unger EF, Thompson AM, Blank MJ, et al. Erythropoiesis-stimulating agents: time for a revaluation. N Engl J Med 2010;362:189-92
43. Lawler EV, Bradbury BD, Fonda JR, et al. Transfusion burden among patients with chronic kidney disease and anemia. Clin J Am Soc Nephrol 2010;5(4):667-72
44. Strippoli GF, Navaneethan SD, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 2006(4):CD003967
45. Anaemia Work Group for National Kidney Foundation - Dialysis Outcomes Quality Initiative (NKF-DOQI). Clinical practice guidelines for the treatment of anaemia of chronic renal failure. Am J Kidney Dis 1997;30(Suppl 3):192-240
46. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease, 2007 Update of Hemoglobin Target. Am J Kidney Dis 2007; 49(Suppl):S1-S182
47. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;335:2085-98 (Pubitemid 44749317)
48. Messana JM, Chuang CC, Turenne M, et al. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model. Am J Kidney Dis 2009;53:503-12
49. Pfeffer MA, Burdmann EA, Chen CY, et al. TREAT investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32
50. Winkelmayer WC. Against TREATing all patients alike: lessons from an FDA advisory committee meeting. J Am Soc Nephrol 2011;22(1):2
51. Locatelli F, Del Vecchio L. Debate: CON Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed? Am J Nephrol 2010;31(6):557-60; discussion 561-562
52. Locatelli F, Del Vecchio L, Casartelli D. Darbepoetin alfa and chronic kidney disease. N Engl J Med 2010;362(7):654-5
53. Locatelli F, Aljama P, Canaud B, et al. Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant 2010;25(9):2846-50
54. Available from: http://www.fda.gov/ NewsEvents/Newsroom/ PressAnnouncements/ucm260670.htm [Last visited 21 October 2011]
55. Locatelli F, Del Vecchio L, Pozzoni P. Pure red-cell aplasia 'epidemic': mystery completely revealed? Perit Dial Int 2007;27(Suppl 2):S303-7 (Pubitemid 350047719)
56. Del Vecchio L, Cavalli A, Tucci B, Locatelli F. Chronic kidney disease-associated anemia: new remedies. Curr Opin Investig Drugs 2010;11(9):1030-8
57. Locatelli F, Aljama P, Barany P, et al. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl 2):ii1-47